Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy

Paul Sorajja, Steve R. Ommen, David R. Holmes, Joseph A. Dearani, Charanjit S. Rihal, Bernard J. Gersh, Ryan J. Lennon, Rick A. Nishimura

Research output: Contribution to journalArticlepeer-review

187 Scopus citations


BACKGROUND-: The clinical efficacy of alcohol septal ablation for obstructive hypertrophic cardiomyopathy (HCM) has been demonstrated, but the long-term effects of the procedure remain uncertain. This study examined the survival of patients after septal ablation performed in a tertiary HCM referral center. METHODS AND RESULTS-: We examined 177 patients (mean age, 64 years; 68% women) who underwent septal ablation at our institution. Over a follow-up of 5.7 years, survival free of all mortality was no different than the expected survival for a comparable general population, and similar to that of age- and sex-matched patients who underwent isolated surgical myectomy (8-year survival estimate, 79% versus 79%; P=0.64). For the end point of documented sudden cardiac death or unknown cause of death, the incidence per 100 person-year follow-up was 1.31 (95% confidence interval, 0.60-2.38). Residual left ventricular outflow tract gradient after ablation was an independent predictor of long-term survival free of any death. CONCLUSIONS-: In this nonrandomized study of carefully selected patients undergoing septal ablation by experienced operators in a tertiary referral HCM center, long-term survival was favorable and similar to that of an age- and sex-matched general population, and to patients undergoing surgical myectomy, as well, without an increased risk of sudden cardiac death.

Original languageEnglish (US)
Pages (from-to)2374-2380
Number of pages7
Issue number20
StatePublished - Nov 13 2012


  • ablation
  • alcohol
  • cardiomyopathy
  • prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy'. Together they form a unique fingerprint.

Cite this